NCT00137007已完成4 期
A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 151
- 主要终点
- To evaluate the clinical efficacy of intravenous (IV) azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams twice a day (BID) for 2 to 5 days
研究概览
简要总结
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide.
This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must require hospitalization and intravenous therapy.
- •Subjects must have a Fine pneumonia score > 70 (Fine Class > II).
- •Subjects must have a medical history and clinical and radiological findings consistent with a community-acquired bronchopneumonia or lobar pneumonia. The following criteria must be met:
- •new infiltrate(s) on chest X-ray; AND
- •at least two of the CAP signs or symptoms.
排除标准
- •Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the baseline visit, or treatment for more than 7 days within 15 days.
- •Specific systemic diseases or other medical conditions that would interfere with the evaluation of the therapeutic response or safety of the study drug, including:
- •Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis carinii pneumonia;
- •Neutropenia;
- •Cavitary lung disease by chest X-ray;
- •Primary lung cancer or other malignancy metastatic to the lung;
- •Aspiration pneumonia;
- •Known or suspected tuberculosis;
- •Neoplastic disease;
- •Cystic fibrosis;
- •A history of any form of epilepsy or seizure;
- •Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia (this does not exclude patients with chronic obstructive pulmonary disease);
- •Significant gastrointestinal or other conditions which may affect study drug absorption; and
- •Significant cardiovascular disorders.
- •Immunosuppressive therapy, defined as chronic treatment with known immunosuppressant medications
- •Impaired hepatic function, as shown by, but not limited to, AST, (SGOT), or ALT (SGPT) greater than three times the laboratory upper limit of normal, or total bilirubin greater than two times the upper limit of normal.
- •Subjects already hospitalized or who resided in a long-term-care facility for greater than 14 days before the onset of symptoms.
结局指标
主要结局
To evaluate the clinical efficacy of intravenous (IV) azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams twice a day (BID) for 2 to 5 days
followed by oral azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams.
次要结局
- To evaluate the eradication of baseline pathogens of IV azithromycin plus IV ampicillin/sulbactam followed by oral azithromycin plus IV ampicillin/sulbactam at Visit 3 and Visit 4
研究者
相似试验
已完成
不适用
An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)Mycobacterium Avium-Intracellulare InfectionHIV InfectionsNCT00002090Pfizer
已完成
2 期
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm InfantsUreaplasma InfectionsNCT01778634University of Maryland, Baltimore121
Unknown
4 期
Azithromycin in Hospitalized COVID-19 PatientsCOVID-19NCT04359316Shahid Beheshti University of Medical Sciences40
已完成
3 期
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult PatientsPneumoniaNCT00643734Pfizer468
已完成
2 期
Azithromycin Combination Therapy for the Treatment of Severe MalariaFalciparum MalariaNCT01374126Medical University of Vienna75